Patents Examined by Delbert R. Philips
-
Patent number: 4916118Abstract: The present invention relates to pharmaceutical administration systems containing phosphatidylserine and phosphatidylcholine or phosphatidylethanolamine derivatives in the form of liposomes which encapsulate chemotactic peptides such as N-formyl-L-methionyl-L-leucyl-L-phenylalanine. The liposomes are prepared by conventional dispersion methods. The pharmaceutical administration systems when applied in the form of liposomes stimulate macrophage activity which is especially useful in the cancer therapy for combating metastatic tumor cells and for treatment of chronic infections.Type: GrantFiled: August 12, 1987Date of Patent: April 10, 1990Assignee: Board of Regents, The University of Texas SystemInventors: Isaiah J. Fidler, Kiyoshi Morikawa, Rajiv Nayar
-
Patent number: 4716147Abstract: Novel synthetic atrial peptides are provided with enhanced natriuretic properties by substituting one or two arginine residues for the N-terminal ser-ser in atriopeptins I, II and III and their physiologically acceptable salts, esters and amides.Type: GrantFiled: March 27, 1986Date of Patent: December 29, 1987Assignee: Monsanto CompanyInventors: Foe S. Tjoeng, Kam F. Fok, Steven P. Adams
-
Patent number: 4525300Abstract: An antibody of a human leukemia virus-related peptide obtained by collecting an antibody produced in a mammal body by administering to the mammal an antigen prepared by reacting a human leukemia virus-related peptide selected from the group consisting of:(a) a peptide represented by formula (1):H-Tyr-Val-Glu-Pro-Thr-Ala-Pro-Gln-Val-Leu-H (1)(b) a peptide represented by formula (2):R-Ile-Pro-His-Pro-Lys-Asn-Ser-Ile-Gly-Gly-Glu-Val-OH (2)wherein R is the same as drefined above;(c) a peptide represented by formula (3):R-Thr-Trp-Thr-Pro-Lys-Asp-Lys-Thr-Lys-Val-Leu-OH (3)wherein R is the same as defined above;(d) a peptide represented by formula (4):H-Val-Val-Gln-Pro-Lys-Lys-Pro-Pro-Pro-Tyr-OH (4)(e) a peptide represented by formula (5):R-Met-Gly-Gln-Ile-Phe-Ser-Arg-Ser-Ala-Ser-Pro-OH (5)wherein R is the same as defined above; and(f) a peptide represented by formula (6):H-Tyr-Pro-Glu-Gly-Thr-Pro-Lys-Asp-Pro-Ile-Leu-Arg-Ser-Leu-OH (6)as a hapten, with a carrier in the presence of a hapten-carrier binding agent.Type: GrantFiled: September 23, 1983Date of Patent: June 25, 1985Assignees: Japanese Foundation for Cancer Research, Otsuka Pharmaceutical Co., Ltd.Inventors: Mitsuaki Yoshida, Haruo Sugano, Fumio Shimizu, Kenichi Imagawa
-
Patent number: 4515920Abstract: Solid phase synthesis of peptides and proteins have been improved by the use of a trifunctional segment, one functional group of which is bound to a solid support, the other two functional groups being available as substrates upon which identical proteins are synthesized.Type: GrantFiled: April 30, 1984Date of Patent: May 7, 1985Assignee: The Rockefeller UniversityInventor: Bruce W. Erickson
-
Patent number: 4293482Abstract: A-30912A nucleus, which is prepared by enzymatic deacylation of an antibiotic selected from A-30912 factor A, tetrahydro-A-30912A, and aculeacin A using an enzyme produced by the Actinoplanaceae, preferably by Actinoplanes utahensis. A-30912A nucleus and salts thereof are useful intermediates to prepare new semi-synthetic antifungal agents.Type: GrantFiled: August 25, 1980Date of Patent: October 6, 1981Assignee: Eli Lilly and CompanyInventors: Bernard J. Abbott, David S. Fukuda
-
Patent number: 4276282Abstract: The present invention relates to processes for an easily applicable industrial production of interferon and the possibilities of the products for preventing and treating interferonsensitive diseases.The process easily produces a large amount of interferon and transplanting established human cells to other warm-blooded animals or inoculating the cells in a diffusion chamber and multiplying the cells therein while allowing the animals to supply the cells with their nutrient body fluids, then exposing in vivo or in vitro the resultant cells to the action of interferon inducer. The present invention is also based on the discovery that the interferon obtained by the present method is an effective and superior preparation for preventing and treating interferon-sensitive diseases.Type: GrantFiled: January 22, 1979Date of Patent: June 30, 1981Assignees: Ken Hayashibara, Shin AshidaInventors: Kaname Sugimoto, Shokichi Yuen
-
Patent number: 4049829Abstract: The present invention concerns as new industrial products, hydroxy-thioalkanes of the formula:Ti Ho--A--S--(CH.sub.2).sub.n --S--A--OHwhere n is an integer from 5 to 15 and A is a straight or branched C.sub.2 -C.sub.6 hydrocarbon chain which may also comprise an OH group.The compounds of formula I are useful in therapeutics, notably as hypolipemiant and hypocholesterolemiant agents.Type: GrantFiled: September 18, 1975Date of Patent: September 20, 1977Assignee: Societe anonyme dite: Laboratoire L. LafonInventor: Louis Lafon
-
Patent number: 4028318Abstract: Chromogenic substrates for serine proteases, represented by the formula:R.sub.1 -A.sub.1 -A.sub.2 -Gly-Arg-NH-R.sub.2or its salts, where R.sub.1 is hydrogen or alkanoyl having from 1 to 12 carbon atoms or cyclohexylcarbonyl or benzoyl or benzoyl substituted with one or two halogen atoms, methylamine or phenyl groups or benzene sulphonyl or toluenesulphonyl, R.sub.2 is nitrophenyl or naphthyl or nitronaphthyl or methoxynaphthyl or quinolyl or nitroquinolyl, A.sub.1 is a single bond or one of the amino acids Gly, Ala, Val, Leu, Ileu, Pro, Met, Phe or Tyr, and A.sub.2 is one of the amino acids Glu, Gln, Asp, or Asn.Type: GrantFiled: November 14, 1975Date of Patent: June 7, 1977Assignee: A B KabiInventors: Leif Erik Aurell, Karl Goran Claeson